According to a story from pharmalive.com, the drug company Calliditas Therapeutics will plan to seek approval for its therapy Nefecon from the US Food and Drug Administration (FDA). This approval…
According to a story from BioSpace, a recent study conducted by the biotechnology company Goldfinch Bio in collaboration with academic partners is highlighting the importance of proteinuria in determining outcomes…
According to a press release, biopharmaceutical company Apellis Pharmaceuticals ("Apellis") recently launched registration programs to explore pegcetacoplan for patients with C3 glomerulopathy (C3G), amyotrophic lateral sclerosis (ALS), and immune…
We are learning more everyday about COVID-19. We know that for most people who contract the disease, recovery will be swift and they will return to normal rather quickly. However,…
There's no misunderstanding this fact: renal-replacement therapy is effective for patients with severe acute kidney injuries (AKI). However, states Kenny Walter in MD Magazine, the efficacy of this treatment can depend…
Lupus nephritis causes kidney inflammation and can often lead to chronic kidney disease (CKD). An issue that medical professionals have faced is predicting the likelihood of individual patients developing CKD.…
According to a story from Physician's Weekly, while measuring the concentration of albumin (albuminuria) is widely considered the standard method for staging and screening for chronic kidney disease, a different…
According to a story from Physician's Weekly, a recent study has concluded that the drug allopurinol is not capable of slowing down the progression of chronic kidney disease. The research,…
This morning, SynAct Pharma AB announced in a press release that they began a Phase II clinical trial to determine the efficacy and safety of AP1189 on treating patients with…
It is crazy to think back to a few months ago and see how much has changed. In March, SARS-CoV-2, which you probably know as COVID-19, was declared a global…
Over 200,000 people in the United States are affected by acute kidney injury (AKI) every year, with an additional 13 million people across the world also experiencing it. Acute kidney…
According to a story from BioSpace, the biopharmaceutical company Retrophin, Inc., recently announced that the first patient has been treated in the company's Phase 3 clinical trial testing sparsentan as…
According to Business Wire, a pharmaceutical company, Aurinia Pharmaceuticals Inc., recently announced that they have enrolled the first lupus nephritis patients in the AURORA 2 extension study. Not only this, but Aurinia…
The biopharmaceutical company Complexa, Inc., has announced that the first patient has been dosed on the Phase 2 clinical trial FIRSTx. FIRSTx is a study of the experimental drug CXA-10…
The phase 3 trial of the drug Inlyta for the treatment of patients with a high risk of recurrent renal cell carcinoma (kidney cancer) following nephrectomy (removal of a kidney)…
Research into graft-versus-host-disease (GVHD), a condition that can occur after bone marrow transplants, has yielded promising results. A study, reported by BrightSurf, found that a particular group of microRNA molecules involved…
© Copyright Patient Worthy
